Imatinib Hexal (Imatinib)

Imatinib Hexal belongs to the tyrosine kinase inhibitor class and is indicated for malignancies driven by BCR‑ABL or related kinases.

• Chronic myeloid leukemia (CML): helps achieve and maintain cytogenetic and molecular remission.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to complete remission when combined with chemotherapy.
• Gastrointestinal stromal tumor (GIST): reduces tumor growth and prolongs progression‑free survival.

• Imatinib selectively inhibits the BCR‑ABL tyrosine kinase as well as KIT and PDGFR kinases. By blocking these enzymes, it prevents downstream signaling that drives uncontrolled cell proliferation and survival, leading to apoptosis of malignant cells that depend on these pathways.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools, often transient.
• Edema: swelling of the ankles or feet.
• Fatigue: general tiredness.
• Muscle cramps: intermittent muscle tightness.
• Rash: skin redness or itching.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Myelosuppression: decreased blood cell counts leading to infection or bleeding.
• Cardiotoxicity: heart failure or reduced ejection fraction.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Pulmonary arterial hypertension: shortness of breath and fatigue.
• Renal impairment: reduced kidney function.

Before initiating therapy, clinicians should evaluate patient history and laboratory values.

• Baseline labs: obtain complete blood count, liver and renal function tests.
• Hepatic monitoring: repeat liver enzymes periodically during treatment.
• Cardiac assessment: evaluate cardiac function in patients with pre‑existing heart disease.
• Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Imatinib interacts with several drug classes that may alter its exposure or toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib plasma levels and toxicity.
• Strong CYP3A4 inducers (e.g., rifampicin, phenytoin): may reduce efficacy by lowering drug concentrations.

Moderate Interactions (Monitor Closely)

• Acid‑reducing agents (e.g., proton pump inhibitors, antacids): can modestly decrease absorption.
• Concomitant anticoagulants (e.g., warfarin): may enhance bleeding risk.
• Vaccines: live attenuated vaccines should be avoided during therapy.